



Insulet to Share Omnipod Clinical Data at Three Major European National Diabetes Congresses

March 14, 2018

Strong Presence at National Professional Diabetes Congresses in the UK, France and Germany Demonstrates Insulet's Commitment to the European Diabetes Community

BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 14, 2018-- Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in [tubeless insulin pump](#) technology with its Omnipod® Insulin Management System (Omnipod System), announced that it will have a strong presence at three leading national diabetes congresses in Europe over the coming months:

- Diabetes UK Professional Conference (Diabetes UK), March 14-16 at ExCeL, London
- Société Francophone du Diabète (SFD) Annual Conference, March 20-23 at Cité des Congrès de Nantes, France
- Deutsche Diabetes Gesellschaft (DDG) Diabetes Kongress, May 9-12 at CityCube Berlin, Germany

Insulet will have a booth presence at each meeting to allow its fast-growing European team to interact directly with the diabetes community. Additionally, at Diabetes UK, Insulet will hold a sponsored symposium, "The Omnipod Insulin Management System: Real-world use and future innovation" on Thursday, March 15, in Room 1 from 6:35–7:35 p.m. (local time). Healthcare professionals attending these congresses will also have the opportunity take the "Pod Challenge" to experience first-hand the simplicity and ease of use that the Omnipod System offers users globally.

The Company's presence at these major European meetings will provide a platform for the local Insulet teams to more broadly communicate the Company's plans to transition to direct operations in Europe to distribute and support its Omnipod System on July 1, 2018. The latest news about the transition in Europe is available at <https://www.omnipodeurope.com>.

"We are excited to attend these important national congresses and support the diabetes communities in Europe," said Patrick Sullivan, Chairman and Chief Executive Officer. "We are confident our local teams have the experience and talent necessary to transition this business successfully and to drive increased value for our customers and all of our stakeholders."

About the Omnipod Insulin Management System:

The Omnipod Insulin Management System is an innovative continuous insulin delivery system that provides all the proven benefits of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System's innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod's auto-cannula insertion is quick, simple, and virtually pain-free. Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod's automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user's programmed basal rate.

The Omnipod System is the world's first commercially available tubeless insulin delivery system that allows users to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.

About Insulet Corporation:

Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet's Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and <https://www.omnipodeurope.com>.*

*Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties

described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180314005258/en/>

Source: Insulet Corporation

Insulet Corporation

Investor Relations and Corporate Media:

Deborah R. Gordon, 978-600-7717

Vice President, Investor Relations and Corporate Communications

dgordon@insulet.com

or

International Media:

Dominic Hulton, +44 20 3941 5374

Vice President, Marketing, Europe

dhulton@insulet.com